Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Alto Neuroscience, Inc. ( (ANRO) ) has shared an announcement.
On April 1, 2026, Alto Neuroscience reported topline Phase 2 proof-of-concept data for ALTO-101 in cognitive impairment associated with schizophrenia, showing no statistically significant benefit on primary EEG or cognitive endpoints versus placebo. The trial did reveal directional EEG improvements, including a near-significant theta-ITC signal and nominal significance in a more impaired subgroup, with tolerability comparable to placebo and potential advantages over traditional PDE4 inhibitors.
Alto has created a modified-release, once-daily oral formulation of ALTO-101 with improved pharmacokinetics and tolerability and plans to seek partners rather than independently advance the asset in CIAS. The company is reallocating resources to its lead program, ALTO-207 for treatment-resistant depression, which has supportive prior clinical data and is expected to enter a Phase 2b trial in the first half of 2026, backed by a strong cash position and a broader pipeline in precision psychiatry.
The most recent analyst rating on (ANRO) stock is a Hold with a $23.00 price target. To see the full list of analyst forecasts on Alto Neuroscience, Inc. stock, see the ANRO Stock Forecast page.
Spark’s Take on ANRO Stock
According to Spark, TipRanks’ AI Analyst, ANRO is a Neutral.
The score is held back primarily by weak financial performance (no revenue, sizable losses, and significant cash burn). Offsetting this, the stock shows constructive technical momentum (price above major moving averages with positive MACD) and a supportive corporate event (large PIPE financing improving cash resources). Valuation is neutral-to-weak given the negative P/E and no dividend yield.
To see Spark’s full report on ANRO stock, click here.
More about Alto Neuroscience, Inc.
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, using its Precision Psychiatry Platform to match brain biomarkers with targeted therapies. Its pipeline spans bipolar depression, major depressive disorder, treatment-resistant depression, schizophrenia and other mental health conditions, aiming to deliver more personalized treatment options.
Average Trading Volume: 245,086
Technical Sentiment Signal: Buy
Current Market Cap: $718.1M
For a thorough assessment of ANRO stock, go to TipRanks’ Stock Analysis page.